Fund manager pleads guilty to insider trading

Former FrontPoint fund manager Joseph Skowron pleaded guilty to an insider trading charge related to Human Genome Sciences' hepatitis C drug. Skowron received tips on clinical trials outcomes from hepatitis C expert and former HGS advisor Yves Benhamou that helped his fund avoid more than $30 million in losses, according to Bloomberg. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.